Advanced Solid Tumors, PARP Inhibitor
Conditions
Keywords
SPR1020
Brief summary
This study is a multicenter, open-label study designed to evaluate SPR1020 in adult patients with advanced solid tumors. The study aims to characterize the safety, tolerability, pharmacokinetic (PK) profile, and preliminary antitumor activity of SPR1020 monotherapy in this population. The study consists of two parts: Phase I component (dose escalation and backfill) and Phase II component (dose expansion). The primary objectives of the Phase I part are to investigate the safety, tolerability, and PK profile of SPR1020 and to determine the Recommended Phase II Dose (RP2D) and/or the Maximum Tolerated Dose (MTD), if attainable. The Phase II part will be initiated once the RP2D and/or MTD is established in the Phase I part. As a new-generation, highly selective PARP1 inhibitor, SPR1020 demonstrates a competitive clinical benefit-risk profile, combining potential intracranial activity with a differentiated safety profile. By leveraging a "synthetic lethality" mechanism, SPR1020 is expected to demonstrate significant efficacy against tumors harboring BRCA mutations or homologous recombination repair (HRR) pathway gene alterations (e.g., breast cancer, prostate cancer). Owing to its high selectivity for PARP1 over PARP2, SPR1020 may circumvent the hematological toxicities associated with PARP2 inhibition by first-generation pan-PARP inhibitors (e.g., olaparib), potentially resulting in an improved safety profile. This enhanced safety may provide greater flexibility for use in combination therapies. Furthermore, SPR1020's ability to penetrate the blood-brain barrier could offer a new treatment option for patients with advanced disease and brain metastases, addressing a high unmet medical need in this population with limited therapeutic choices. Preclinical data support this differentiated profile in terms of both efficacy and toxicity. Hypothesis: SPR1020 represents a novel anticancer therapeutic with the potential for enhanced efficacy and an improved safety profile. The overall assessment indicates that its clinical benefits outweigh the potential risks. This study has been approved by the IEC and adheres to the principles of the Declaration of Helsinki.
Interventions
DRUGSRP1020
SPR1020 is administered orally. The dosing frequency is once daily (QD). Each treatment cycle is 21 days.
Sponsors
Shanghai SciBrunch Therapeutics Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female subjets ≥ 18 years old. 2. Phase I Dose-Escalation Part: Patients with histologically or cytologically confirmed, surgically unresectable, locally advanced or metastatic malignant solid tumors, who have experienced failure of standard therapy, or for whom no standard therapy exists, or who are intolerant to standard therapy. (Priority will be given to enrolling patients with breast, ovarian, prostate, or pancreatic cancer harboring homologous recombination deficiency (HRD)-related gene mutations such as BRCA1/2, PALB2, RAD51C/D). Phase I Dose Backfill Portion: Patients with HER2-negative breast cancer (BC), advanced epithelial ovarian cancer (OC)/fallopian tube cancer (FTC)/primary peritoneal cancer (PPC), or castration-resistant prostate cancer (CRPC), who have a documented pathogenic or likely pathogenic BRCA mutation (BRCAm, germline or somatic) as detected by a local or central laboratory, and who have experienced failure of at least one prior line of standard anticancer therapy (refer to the protocol section for the Phase II dose expansion for specific standard therapy requirements); Or patients with other tumor types harboring homologous recombination deficiency (HRD) related gene mutations (including but not limited to esophageal cancer, small cell lung cancer, or pancreatic cancer) who have experienced failure of at least one prior line of standard therapy. Phase II Dose Expansion Study: Allows prior treatment with a pan-PARP inhibitor (no more than 1 type). Specific requirements for each cohort are as follows: Cohort 1: Breast Cancer (BC): 1. Histologically or cytologically confirmed HER2-negative (HR+/HER2- or triple-negative) advanced or metastatic breast cancer. 2. Presence of a predicted loss-of-function BRCA1/2 mutation in germline or tumor tissue. 3. Received at least \> 1 line of systemic therapy for advanced disease (must have received at least one line of chemotherapy; if HR+, must have received endocrine therapy), with recent radiological confirmation of disease progression. Cohort 2: Ovarian Cancer (OC): 1. Histologically confirmed high-grade serous or endometrioid ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. 2. Presence of a predicted loss-of-function BRCA1/2 mutation in germline or tumor tissue. 3. Received at least \> 1 line of systemic therapy for advanced disease (must have received at least one platinum-based chemotherapy regimen for advanced disease), with recent radiological confirmation of disease progression. 4. Subjects must have a response duration of ≥ 6 months after the last platinum-based chemotherapy (platinum-sensitive population). Cohort 3: Prostate Cancer (PC): 1. Histologically or cytologically confirmed prostatic adenocarcinoma, which has progressed to the castration-resistant stage. 2. Ongoing androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone analog or status post bilateral orchiectomy, with serum testosterone \< 50 ng/dL (\< 1.73 nmol/L) within 28 days prior to study enrollment. Patients receiving ADT at the time of enrollment should continue this therapy throughout the study period. 3. Presence of a predicted loss-of-function BRCA1/2 mutation in germline or tumor tissue. 4. Received at least \> 2 lines of systemic therapy for advanced disease (must have received a novel hormonal agent \[NHA\] and chemotherapy), with recent radiological confirmation of disease progression. Cohort 4: 1\) The aforementioned tumor types (from Cohorts 1-3) harboring HRRm (excluding BRCA mutations), or other tumor types harboring HRRm (including but not limited to esophageal cancer, small cell lung cancer, or pancreatic cancer, etc.), which have failed after first-line or later standard therapy. 3\. Presence of at least one measurable lesion according to RECIST v1.1. 4. For both Phase I backfill and Phase II expansion, patients must provide tumor tissue (archived specimen from within 12 months pre-ICF preferred; fresh biopsy if unavailable) and peripheral blood for BRCAm/HRRm testing. Provision of specimens is also encouraged for Phase I dose-escalation patients when feasible. Testing will be conducted at a Sponsor-designated central laboratory. The samples provided shall comply with the following requirements: * Option 1 : 8-10 sections of surgically resected tumor tissue specimens, or 10-15 sections of core needle biopsy specimens; fine needle aspiration specimens are not acceptable; plus approximately 2 mL of peripheral blood. * Option 2 : If tumor tissue samples cannot be provided, a peripheral blood sample of approximately 10 mL may be provided instead. Note:BRCAm/HRRm results must meet eligibility criteria. A prior positive local laboratory report is acceptable for enrollment without awaiting central lab results; the central report will serve for retrospective validation. If sample quantity is insufficient, Sponsor consultation is required for enrollment eligibility. 5\. ECOG Performance Status of 0-1. 6. Expected survival time ≥ 3 months. 7. Adequate organ function: a. Hematopoietic system (Has not received blood transfusion or hematopoietic growth factor therapy within 14 days): i. Platelet count ≥ 100 × 10\^9/L ii. Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L iii. White blood cell count ≥ 3.0 × 10\^9/L iv. Hemoglobin ≥ 90 g/L b. Hepatic function: i. Total bilirubin ≤ 1.5 × ULN ii. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN (in the absence of liver metastases) iii. ALT and AST ≤ 5.0 × ULN (In subjects with liver metastases) c. Renal function: i. Creatinine clearance (Ccr) \> 50 mL/min (calculated by the Cockcroft-Gault formula) d. Coagulation function: i. Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN ii. International normalized ratio (INR) ≤ 1.5 × ULN 8. Both PARPi-pretreated and PARPi-naive patients are eligible for enrollment. For PARPi-pretreated patients, they are allowed to have received a maximum of one prior line of PARPi-containing therapy (whether as monotherapy or as maintenance therapy). 9\. Women of childbearing potential (WOCBP) (defined as those not surgically sterile or from menarche until 1 year after menopause) must have a negative serum pregnancy test result within 7 days prior to the first dose of the IP. WOCBP must agree to practice abstinence or use highly effective contraceptive methods from the time of signing the informed consent form until 3 months after the last dose of the IP. Similarly, male subjects (including those post-vasectomy) must agree to use effective contraception or practice abstinence from the time of signing the informed consent until 3 months after the last dose of the IP, and must refrain from sperm donation during this period. 10\. The subject must provide informed consent for the study prior to any trial-related procedures and voluntarily sign the written informed consent form.
Exclusion criteria
1. Have received systemic anti-tumor therapy (including chemotherapy, biotherapy, endocrine therapy, immunotherapy, etc.) within 4 weeks prior to the first dose of the investigational product, with the following specifics: mitomycin and nitrosoureas within 6 weeks from the last dose; oral fluorouracil drugs (such as tegafur and capecitabine) within 2 weeks from the last dose; small molecule targeted agents within 2 weeks or 5 half-lives from the last dose, whichever is shorter; have received any herbal or botanical products with purported anti-tumor effects within 2 weeks prior to the first dose of the investigational product. 2. Have received radiotherapy (with the exception of palliative radiotherapy) within 3 weeks prior to the initiation of study treatment, or have a history of radiation pneumonitis. Note: With the exception of a history of radiation pneumonitis, subjects must have recovered from all radiation-related toxicities. 3. Have received other unapproved investigational drugs within 4 weeks prior to the first dose of the investigational product, or within 5 half-lives of the other drug(s), whichever is shorter. 4. Have undergone major organ surgery (excluding Puncture Biopsy) within 4 weeks prior to the first dose of the investigational product, or have experienced significant trauma, or require elective surgery during the trial period. 5. Prior treatment with a PARP1 inhibitor. Note: For subjects enrolling in the dose-escalation phase, enrollment may be considered following discussion with and agreement from the sponsor's medical representative. 6. Have received or are anticipated to require long-term systemic glucocorticoid therapy (prednisone \>10 mg/day or equivalent) or other immunosuppressive therapy within 14 days prior to the first dose of the investigational product. The following are exceptions: topical, intra-articular, intranasal, and inhaled corticosteroids; corticosteroid administration as premedication for contrast-enhanced imaging studies to prevent allergic reactions; short-term (≤ 7 days) use of corticosteroids for the prevention or treatment of non-autoimmune allergic conditions; and glucocorticoids used during the treatment stage for castration-resistant prostate cancer (CRPC). 7. Have used immunomodulatory agents, including but not limited to thymic peptides, interleukin-2 (IL-2), interferon, etc., within 14 days prior to the first dose of the investigational product. 8. Have received a live or attenuated live vaccine within 4 weeks prior to the first dose of the investigational product. Inactivated vaccines are permitted. 9. Have used within 7 days prior to the first dose of the investigational product or require concomitant use during the study treatment period of medications, herbal supplements, or foods known to be strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers (refer to Appendix 4 a summary list of common CYP3A4 enzyme inducers and inhibitors). 10. Have a prior history of allogeneic bone marrow transplantation or solid organ transplantation. 11. Patients with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or presenting with features suggestive of MDS/AML. 12. Have difficulty swallowing oral medications, or have malabsorption syndrome or any other poorly controlled gastrointestinal disease that may affect bioavailability. 13. Adverse reactions from prior anti-tumor therapy have not recovered to ≤ Grade 1 per CTCAE v5.0 (except for alopecia, hyperpigmentation, and other tolerable events judged by the investigator) or to the level specified in the protocol inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| DLT/MTD | Within 24 days after the first dose (including 3 days of Cycle 0 and 21 days of Cycle 1) | Incidence and characteristics of Dose-Limiting Toxicity (DLT) to determine the Maximum Tolerated Dose (MTD). |
| RP2D | From the first dose until disease progresses or end of treatment for other reasons，up to 1 year | Recommended Phase II Dose (RP2D) of SPR1020, as the dose for efficacy study in Phase II, will be the dose with promising clinical responses observed in the patients, and well tolerated by patients. |
| Incidence and characteristics of AEs and SAEs (according to NCI CTCAE 5.0) | All AEs/SAEs (including irAEs/AESIs) will be collected from first dose until 30 days after the last dose, or until new anti-tumor therapy begins，up to 1 year | Incidence and characteristics of Adverse Events (AEs) and Serious Adverse Events (SAEs) throughout the study period, were evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) V5.0. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ORR | From date of first dose until the date of first documented progression, death from any cause, loss of follow-up, withdrawal of informed consent, or study termination by the sponsor, whichever came first，up to 1 year | Objective Response Rate (ORR) is the proportion of patients with Complete Response (CR) or Partial Response (PR). ORR and other efficacy evaluation indexes are based on RECIST 1.1 criteria |
| DCR | From date of first dose until the date of first documented progression, death from any cause, loss of follow-up, withdrawal of informed consent, or study termination by the sponsor, whichever came first，up to 1 year | Disease control rate (DCR) is the proportion of patients with CR, PR, and Stable Disease (SD). |
| DOR | From date of first dose until the date of first documented progression, death from any cause, loss of follow-up, withdrawal of informed consent, or study termination by the sponsor, whichever came first，up to 1 year | Duration of Response (DOR) is the time between the first onset of CR or PR and the first onset of Disease Progression (PD) or death from any cause. |
| PFS | From date of first dose until the date of first documented progression, death from any cause, loss of follow-up, withdrawal of informed consent, or study termination by the sponsor, whichever came first，up to 1 year | Progression-Free Survival (PFS) is the time between first initiation of study treatment to PD or death due to any reason. |
| OS | From date of first dose until the date of first documented progression, death from any cause, loss of follow-up, withdrawal of informed consent, or study termination by the sponsor, whichever came first，up to 1 year | Overall Survival (OS) is defined as the time interval from the date of the first dose of study drug to the date of death from any cause. |
| Cmax | Up to approximately 189 days(Cycle 9 Day 1，a cycle for 21 days) | Peak concentration (Cmax). |
| Tmax | Up to approximately 189 days(Cycle 9 Day 1，a cycle for 21 days) | Peak time (Tmax). |
| t1/2 | Up to approximately 189 days(Cycle 9 Day 1，a cycle for 21 days) | Elimination phase half-life (t1/2). |
| AUC0-t | Up to approximately 189 days(Cycle 9 Day 1, a cycle for 21 days) | Area under plasma concentration-time curve from 0 to the last quantifiable time point (AUC0-t). |
| AUC0-∞ | Up to approximately 189 days(Cycle 9 Day 1, a cycle for 21 days) | Area under plasma concentration-time curve from 0 to infinite time (AUC0-∞) |
| AUC0-last | Up to approximately 189 days(Cycle 9 Day 1, a cycle for 21 days) | Area Under the Concentration-Time Curve from Time 0 to Last Quantifiable Concentration. |
| CL | Up to approximately 189 days(Cycle 9 Day 1, a cycle for 21 days ) | Clearance |
| Vd | Up to approximately 189 days(Cycle 9 Day 1, a cycle for 21 days) | Volume of Distribution |
| F | Up to approximately 189 days(Cycle 9 Day 1, a cycle for 21 days) | Bioavailability |
| PARylation | Up to approximately 15 Days | Poly(ADP-ribosyl)ation |
Countries
China
Outcome results
None listed